Portfolio Overview
The Obesity & Metabolic Health Portfolio (ID: 165) continues to track the global opportunity set in obesity and metabolic disease therapeutics. As of July 22, 2026, the portfolio holds seven positions, all within their minimum holding periods. No changes are recommended this week.
Performance Highlights
- Rhythm Pharmaceuticals (RYTM): +18.34% — Strong momentum driven by positive data for setmelanotide in new indications.
- Structure Therapeutics (GPCR): +17.48% — Continued optimism around oral GLP-1 candidates.
- Zealand Pharma (ZLDPF): +6.08% — Steady progress with amylin analog pipeline.
- Altimmune (ALT): -3.44% — Modest pullback; no thesis change.
- Viking Therapeutics (VKTX): -11.44% — Recent weakness on competitive concerns; fundamentals intact.
- Corbus Pharmaceuticals (CRBP): -5.76% — Phase 2 data awaited; near-term volatility expected.
- Carmot Therapeutics (NTLA): -2.15% — Early stage; no material news.
Risk Concentration
The portfolio is concentrated in early-to-mid-stage biotech, with high sensitivity to clinical trial outcomes and regulatory decisions. The obesity theme remains supported by strong demand and innovation, but individual stock volatility is elevated.
What to Watch
- Upcoming data readouts for VKTX and CRBP in Q3 2026.
- Regulatory decisions on RYTM’s expanded label.
- Competitive landscape shifts from Novo Nordisk and Eli Lilly.
Conclusion
All positions remain within their minimum holding periods and no closures are warranted. The portfolio is well-positioned to benefit from the ongoing obesity and metabolic health megatrend.
Disclaimer: This is not investment advice. Past performance is not indicative of future results. Investing in biotech stocks carries significant risk, including loss of principal. Consult a financial advisor before making investment decisions.